ERBB2 and breast carcinoma: reported an HER2 aptamer‐targeted DNA‐NS for lysosomal degradation of tumor‐specific protein molecules and apoptosis by selectively targeting HER2 positive breast cancer.[121] This was achieved by anchoring anti‐HER2 aptamers onto the exterior DNA‐NS resulting in prolonged circulation, higher stability, and improved performance in vivo compared to the free anti‐HER2 aptamer.